In the News

03/01/2018 12:00 AM  | Washington Examiner
02/16/2018 12:00 AM  | PharmaLive
12/20/2017 12:00 AM  | CMPI & NCPA
12/20/2017 12:00 AM  | CMPI & NCPA
07/14/2017 12:00 AM  | CMPI
06/12/2017 12:00 AM  | Morning Consult
05/19/2017 12:00 AM  | National Review
05/18/2017 12:00 AM  | The Institute for Policy Innovation
05/11/2017 12:00 AM  | Morning Consult
05/09/2017 12:00 AM  | LinkedIn
05/09/2017 12:00 AM  | Medscape
Sign Up for Our Email Newsletter

RECENT NEWS

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta...  Read more

FDA  Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15
  • NEWSY
  • 01/04/2022 12:00 AM

FDA Authorizes Pfizer Covid-19 Vaccine Booster for Ages 12-15

CMPI's Peter Pitts discusses FDA approval of Pfizer COVID vaccine booster for children ages 12-15...  Read more

Should We Rethink The FDA Commissionership?

Should We Rethink The FDA Commissionership?

When one considers the FDA’s mission—to independently protect consumers and advance the public health—it is not at all cl...  Read more

DRUGWONKS BLOG